2026
article
OpenAlex
Jooho Chung, Mounica Vallurupalli, Sarah Noel, Gail Schor et autres
Macrophages exert antitumorigenic activity through phagocytosis, but phagocytosis-enhancing therapeutics have not improved acute myeloid leukemia (AML) outcomes. To identify phagocytosis regulators, we performed CRISPR knockout screens in human AML cells cocultured with human macrophages. We found that the "don't eat me" signal …
us, pl
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Laura Doherty, Ashish Bino George, Mustafa Kocak, Paul E. Lund et autres
Abstract PRISM is a highly multiplexed, genomic barcode-based cell line viability technology of nearly 1000 solid tumor and hematopoietic cell lines. The unique cell line barcodes enable the cell lines to be multiplexed into pools of dozens to hundreds of different cell …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Matthew G. Rees, Mustafa Kocak, Matthew J. Emmett, Colleen T. Harrington et autres
Abstract Incomplete understanding of drug mechanism, selectivity, and polypharmacology can contribute to failed clinical trials. Drug candidates are generally characterized with limited pre-clinical tools and a narrow indication focus based on expected target biology. Using approaches such as large-scale PRISM profiling of …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Ian Michael Delahunty, Stephanie Nance, Yang Zhang, François Lamoureux et autres
Abstract Cancer cells are dependent on the control of transcription for maintenance of the malignant cell state. EP300 and CBP are paralogous, commonly expressed, master epigenetic enzymes, whose activity controls normal and malignant transcription. Here, using a cancer-wide integrative chemical-genetic analysis, we …
us, fr
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Colleen T. Harrington, Antonella Masciotti, Ursula Widocki, Laura M. Doherty et autres
Abstract Despite major advances in targeted therapies, cancer remains a leading cause of death among pediatric, adolescent, and adult populations, emphasizing the need for continued therapeutic innovation. The PRISM assay enables large-scale evaluation of oncology agents by barcoding and pooling over 900 …
us
(code pays fourni par la source)
Accès ouvert
2025
preprint
OpenAlex
Rishi V. Puram, Qiangzong Yin, YuhJong Liu, Justine C. Rutter et autres
The DNA-incorporating nucleoside analogs azacytidine (AZA) and decitabine (DEC) have clinical efficacy in blood cancers, yet the precise mechanism by which these agents kill cancer cells has remained unresolved -- specifically, whether their anti-tumor activity arises from conventional DNA damage or DNA …
us, de
(code pays fourni par la source)
Accès ouvert
2025
preprint
OpenAlex
Jooho Chung, Mounica Vallurupalli, Gail Schor, YuhJong Liu et autres
Macrophages in the tumor microenvironment exert potent anti-tumorigenic activity through phagocytosis. Yet therapeutics that enhance macrophage phagocytosis have not improved outcomes in clinical trials for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). To systematically identify regulators of phagocytosis, we …
us, pl
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Laura Doherty, Colleen M. Harrington, Mustafa Kocak, Anthony Fazio et autres
Abstract PRISM is a highly multiplexed, genomic barcode-based cell line viability technology of nearly 1000 solid tumor and hematopoietic cell lines, which enables profiling of cellular responses to small molecules or biologics to discover biomarkers of sensitivity and resistance and generate mechanistic …
us
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Matthew G. Rees, Mustafa Kocak, Matthew J. Emmett, Colleen T. Harrington et autres
Abstract The discovery and development of direct inhibitors of KRAS is transforming therapeutic options across diverse cancer types. Here, we use the PRISM collection of nearly 900 cancer cell lines, including more than 150 KRAS-mutant cell lines, to characterize 19 KRAS-targeting inhibitors …
us
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Jillian N. Eskra, Alvin Kalathungal, Aydin Golabi, Antonella Masciotti et autres
Biologic agents, such as monoclonal antibodies and antibody-drug conjugates (ADCs), have emerged as a highly promising class of the cancer therapeutics due to their ability to target specific tumor antigens with high specificity, be engineered for selective delivery of cytotoxic payloads, and …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Noha A.M. Shendy, Melissa J. Bikowitz, Logan H. Sigua, Yang Zhang et autres
Chemical discovery efforts commonly target individual protein domains. Many proteins, including the EP300/CBP histone acetyltransferases (HATs), contain several targetable domains. EP300/CBP are critical gene-regulatory targets in cancer, with existing high potency inhibitors of either the catalytic HAT domain or protein-binding bromodomain (BRD). …
us
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Ashish Bino George, Shiker Nair, Mustafa Kocak, Ellen Nguyen et autres
Abstract Combination therapies are crucial in cancer care, yet identifying which combination will benefit a specific patient is challenging. The vast array of clinical, investigational, and tool anticancer agents and diverse cancer contexts makes investigating many drug combinations over a large number …
us
(code pays fourni par la source)